Crest Nicholson shares plummet amid profit warning
Housebuilder, Crest, has failed to exploit a benign backdrop in recent years. Should it now merge with rival Bellway? Matthew Partridge reports


Shares in homebuilder Crest Nicholson fell by 11% last Thursday after the company unveiled yet another profit warning, says Melissa Lawford in The Telegraph. But they clawed back most of the lost ground a day later after Crest’s new CEO Martyn Clark said it had turned down an unsolicited £650 million takeover bid from rival Bellway that “significantly undervalued” the business.
However, experts warned that Crest’s recent poor performance means that Clark “will face a difficult turnaround job. Shareholders may have wished management had asked their opinion” before rejecting the bid. Even though Bellway’s all-share offer works out at a 30% premium over Crest’s share price in May, Clark clearly thinks that this is too little, says Joshua Oliver in the Financial Times.
His main concern is that it would value the company at a discount to what he considers to be its “strong land portfolio”. Still, Clark may be too optimistic about Crest’s prospects as a standalone company. It has “struggled, even in the context of widespread gloom in the homebuilding sector”, thanks to “building defects at older sites and buyers put off by high mortgage costs”.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
How is Crest performing?
Crest’s past “prowess at making a horlicks of a market ostensibly loaded in its favour” is dragging down its share price, says Alistair Osborne in The Times. There is also the promise of “more nasties to come” over past problems with cladding and the risk of fire.
Some brokers argue that a merger with Bellway would produce “at least £25 million of synergies” and facilitate the purchase of larger sites. With the top 25 investors in Crest also owning 36% of Bellway, Clark “has a job on proving that a home-alone strategy works best for Crest”.
Already, it seems that some of Crest Nicholson’s biggest shareholders are “pushing” the board to agree some sort of tie-up with Bellway, says Sam Chambers in The Sunday Times. For example, asset management group Schroders, which owns 3% stakes in both companies, is sceptical about the odds of Crest managing to turn itself around as a separate company. It thinks that “the time has come” for Crest “to become part of a larger group”.
Similarly, asset manager abrdn, which also has both companies in its UK Value Equity Fund portfolio, thinks that neither Crest’s board or its shareholders can deny that “there is logic to a combination with Bellway”, though it believes that Bellway’s bid “is not at an appropriate price”.
While Crest’s shareholders may think that Bellway certainly has “scope to offer more” for Crest, it may only require a “nominal hike” to get the deal over the line, says Yawen Chen on Breakingviews.
What’s more, consolidation not only “makes sense for Crest in particular but also for UK builders in general”. Previously “chunky” returns on capital employed “have slumped to single-digit levels”, thanks to “cost inflation and a housing market wrestling with higher interest rates that make it harder for buyers to take the plunge”.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Matthew graduated from the University of Durham in 2004; he then gained an MSc, followed by a PhD at the London School of Economics.
He has previously written for a wide range of publications, including the Guardian and the Economist, and also helped to run a newsletter on terrorism. He has spent time at Lehman Brothers, Citigroup and the consultancy Lombard Street Research.
Matthew is the author of Superinvestors: Lessons from the greatest investors in history, published by Harriman House, which has been translated into several languages. His second book, Investing Explained: The Accessible Guide to Building an Investment Portfolio, is published by Kogan Page.
As senior writer, he writes the shares and politics & economics pages, as well as weekly Blowing It and Great Frauds in History columns He also writes a fortnightly reviews page and trading tips, as well as regular cover stories and multi-page investment focus features.
Follow Matthew on Twitter: @DrMatthewPartri
-
Spring Statement: what could Rachel Reeves say about pensions?
The chancellor will deliver her Spring Statement on 26 March. We look at whether there will be any announcements on pensions that could affect savers or retirees
By Ruth Emery Published
-
Rightmove: Asking prices up again in March as buyers undeterred by looming stamp duty hikes
Average asking prices are up by 1.1% month-on-month and have sustained a 1% growth year-on-year
By Daniel Hilton Published
-
Why CEOs deserve a pay rise
Opinion The CEOs of big companies often come under fire for being grossly overpaid. But the truth, as per some economists, is the opposite. Do they merit a pay rise?
By Stuart Watkins Published
-
Rolls-Royce stock jumps 15% – could it climb further?
Aircraft-engine group Rolls-Royce’s CEO has been hailed as a hero for spearheading the firm’s recovery. And the future looks bright, says Matthew Partridge
By Dr Matthew Partridge Published
-
The power of private markets
Interview Helen Steers, co-manager of the Pantheon International investment trust, tells MoneyWeek about the vast array of compelling opportunities in private equity
By Andrew Van Sickle Published
-
Vertex Pharmaceuticals is an uncommon opportunity in rare diseases
Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success
By Dr Mike Tubbs Published
-
Global investors have overlooked these top tips in emerging markets
Opinion Chris Tennant, co-portfolio manager of Fidelity Emerging Markets, picks three attractive companies in emerging markets
By Chris Tennant Published
-
King Coal has not been dethroned yet — should you buy?
The demand for coal is only growing, yet investors don’t seem to want to take advantage of the opportunity, says Rupert Hargreaves
By Rupert Hargreaves Published
-
It’s time to start buying Europe again, says Merryn Somerset Webb
Opinion Europe's stocks are cheap and the economic backdrop is starting to look cheerier, says Merryn Somerset Webb
By Merryn Somerset Webb Published
-
Prosus to buy Just Eat for €4.1 billion as takeaway boom fades
Food-delivery platform Just Eat has been gobbled up by a Dutch rival. Now there could be further consolidation in the sector
By Dr Matthew Partridge Published